Morgan Stanley Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Intellia Therapeutics (NASDAQ:NTLA) but reduced the price target from $90 to $85.

November 13, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Intellia Therapeutics but lowered the price target from $90 to $85.
While the reduction in price target could suggest a slightly less optimistic outlook, the maintenance of an Overweight rating indicates that Morgan Stanley still has a positive view on the stock's potential. This mixed signal is likely to have a neutral short-term impact on the stock price as the market digests both the positive rating and the lower price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100